{"id":16217,"date":"2026-05-12T12:46:31","date_gmt":"2026-05-12T07:16:31","guid":{"rendered":"https:\/\/translumina.com\/in\/?p=16217"},"modified":"2026-05-12T13:11:03","modified_gmt":"2026-05-12T07:41:03","slug":"elunir-perl-ridaforolimus-and-elastomeric-coating-in-des","status":"publish","type":"post","link":"https:\/\/translumina.com\/in\/blog\/elunir-perl-ridaforolimus-and-elastomeric-coating-in-des\/","title":{"rendered":"EluNIR-PERL\u2122 Ridaforolimus and Elastomeric Coating in DES"},"content":{"rendered":"

In a drug-eluting stent, drug selection and coating integrity directly influence vascular healing and long-term vessel response. EluNIR-PERL\u2122 integrates Ridaforolimus with an Elastomeric Coating engineered to support controlled drug release and surface integrity.<\/span><\/p>\n

 <\/p>\n

Powered by Ridaforolimus<\/b><\/h2>\n

Ridaforolimus is a non-pro-drug analog of rapamycin.<\/span><\/p>\n

Ridaforolimus is not a prodrug; it offers more consistent and predictable drug action, which is desirable in drug-eluting stents for better safety and efficacy.<\/span><\/p>\n

Moreover, Ridaforolimus has a broad therapeutic window. The goal of DES is inhibition of Smooth Muscle Cells (SMC) while not hindering Endothelial Cells (EC) growth.<\/span><\/p>\n

The EC are responsible for the well-being of the blood vessels. In contrast, an accelerated growth of SMC is at the heart of the process of neo-intimal proliferation which ultimately leads to restenosis.<\/span><\/p>\n

As demonstrated, Ridaforolimus presents a good therapeutic window as it inhibits the growth of SMC while minimally affecting the growth of EC. Thus, Ridaforolimus is an appropriate drug to use on a DES.<\/span><\/p>\n

Ridaforolimus offers the optimal therapeutic balance, effectively inhibiting Smooth Muscle Cells proliferation while minimally inhibiting Endothelial Cells growth. It is described as an excellent choice for drug-eluting stents.<\/span><\/p>\n

The drug elution kinetics of Ridaforolimus from an EluNIR Family is similar to the drug elution kinetics of other DES. In addition, Medinol has performed a drug deposition analysis over time. EluNIR Family has a controlled and stable release of drug into the arterial wall.<\/span><\/p>\n

 <\/p>\n

Ridaforolimus Promotes Healthy Endothelialization<\/b><\/h2>\n

EluNIR-PERL\u2122 shows comparable or even better endothelial healing than bare-metal stents which are known for faster healing.<\/span><\/p>\n

EluNIR-PERL\u2122 shows complete endothelialization even at overlap zones by 30 days.<\/span><\/p>\n

Surface of EluNIR-PERL\u2122 shows smooth, continuous cell layer, indicating good endothelial growth.<\/span><\/p>\n

 <\/p>\n

Elastomeric Coating: Improved Surface Quality<\/b><\/h2>\n

Drug performance in a DES is closely linked to coating integrity.<\/span><\/p>\n

Polymer coating irregularities include ridging, flaking, webbing and delamination.<\/span><\/p>\n

The EluNIR-PERL DES has elastic properties that maintains surface integrity, providing controlled drug release.<\/span><\/p>\n

EluNIR-PERL\u2122 incorporates a Unique Elastomeric Coating that expands uniformly\u00a0 with stents..<\/span><\/p>\n

Data on File \u2013 Elastomer: High Elasticity Polymer.<\/span><\/p>\n

 <\/p>\n

Conclusion<\/b><\/h2>\n

EluNIR-PERL\u2122 combines Ridaforolimus and Elastomeric Coating to deliver controlled drug release, surface integrity, and support for endothelial healing.<\/span><\/p>\n

Less Inflammation, More Healing.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

In a drug-eluting stent, drug selection and coating integrity directly influence vascular healing and long-term vessel response. EluNIR-PERL\u2122 integrates Ridaforolimus with an Elastomeric Coating engineered to support controlled drug release and surface integrity.   Powered by Ridaforolimus Ridaforolimus is a non-pro-drug analog of rapamycin. Ridaforolimus is not a prodrug; it offers more consistent and predictable […]<\/p>\n","protected":false},"author":2,"featured_media":16222,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-16217","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"_links":{"self":[{"href":"https:\/\/translumina.com\/in\/wp-json\/wp\/v2\/posts\/16217","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/translumina.com\/in\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/translumina.com\/in\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/translumina.com\/in\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/translumina.com\/in\/wp-json\/wp\/v2\/comments?post=16217"}],"version-history":[{"count":2,"href":"https:\/\/translumina.com\/in\/wp-json\/wp\/v2\/posts\/16217\/revisions"}],"predecessor-version":[{"id":16219,"href":"https:\/\/translumina.com\/in\/wp-json\/wp\/v2\/posts\/16217\/revisions\/16219"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/translumina.com\/in\/wp-json\/wp\/v2\/media\/16222"}],"wp:attachment":[{"href":"https:\/\/translumina.com\/in\/wp-json\/wp\/v2\/media?parent=16217"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/translumina.com\/in\/wp-json\/wp\/v2\/categories?post=16217"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/translumina.com\/in\/wp-json\/wp\/v2\/tags?post=16217"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}